You searched for resistance - Page 8 of 11

Recent Publications of Interest for Chronic Lymphocytic Leukemia (CLL) Patients Related to COVID-19

September 7, 2021

I am introducing eight different research articles and commentaries on COVID-19 that are pertinent to the chronic lymphocytic community, and have informed my personal and institutional response to the demands and opportunities afforded by being one of the most vulnerable during a world-changing pandemic over the past weeks. You can just skim my highlights or use the numerous links to dive deeper.

ASH 2020: Dr. Thomas Kipps on Frontline Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) with High-Risk Genomic Features

August 20, 2021

At the annual meeting of the American Society of Hematology (ASH) 2020, our own Dr. Brian Koffman interviewed Dr. Thomas Kipps, Professor of Medicine at the UC San Diego Moores Cancer Center. They discussed the role of targeted therapies such as ibrutinib for the treatment of CLL with high-risk genomic features.

ASH 2020: Dr. Furman Discusses Minimal Residual Disease-Driven Captivate and Murano Studies in Chronic Lymphocytic Leukemia (CLL)

June 24, 2021

The treatment landscape for those of us with CLL / SLL has changed dramatically in the past decade or less. We see decreasing reliance on chemoimmunotherapies that were the only option in the past. We have seen a move from sequential use of targeted therapies to control our CLL to combinations of drugs that allow patients to attain undetectable MRD.

ASH 2020: Dr. Adrian Wiestner on Early Detection of BTK Mutations Preceding Ibrutinib Relapse in Chronic Lymphocytic Leukemia (CLL)

May 6, 2021

In this ASH 2020 interview, Dr. Adrian Wiestner discusses the usefulness of early detection of BTK mutations.

ASH 2020: Dr. Anthony Mato Discusses the Impact of del(17p) on Survival of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with First-Line Ibrutinib

March 17, 2021

ASH 2019: Dr. David Maloney on CAR-T therapy in CLL (chronic lymphocytic leukemia)

Driving CARs to the Clinic for Standard Medical Management of Chronic Lymphocytic Leukemia (CLL)

March 17, 2021

By Joseph A. Fraietta, PhD The immune system has many ways to fight cancer, one of which is T cells. A common reason for the failure of the immune system to

iwCLL 2019: Dr. Nicole Lamanna on Biomarker Testing for Chronic Lymphocytic Leukemia (CLL)

January 29, 2021

As the science of chronic lymphocytic leukemia has advanced, we have learned much more detailed information about its biology and the specific chromosomes, genes, and proteins that contribute to the disease. Checking for specific abnormalities in chromosomes and genetic variants can help doctors evaluate a patient’s prognosis and predict what treatments might work best.

iwCLL 2019: Dr. Constantine Tam on Clonal Evolution in Chronic Lymphocytic Leukemia (CLL)

December 30, 2020

During iwCLL 2019, Dr. Constantine Tam gave us a look at how the genetics of CLL cells can change over time (clonal evolution) in response to treatment and escape control of that treatment (resistance).

Cellular Immunotherapy in the Management of Cancer

December 7, 2020

By Utkarsh Acharya, DO, FACP Dr. Acharya took amazing care of me when I had my CAR-T therapy in Seattle. He writes a more advanced article about why there is so

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Search Results for: resistance – Page 8

Recent Publications of Interest for Chronic Lymphocytic Leukemia (CLL) Patients Related to COVID-19

ASH 2020: Dr. Thomas Kipps on Frontline Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) with High-Risk Genomic Features

ASH 2020: Dr. Furman Discusses Minimal Residual Disease-Driven Captivate and Murano Studies in Chronic Lymphocytic Leukemia (CLL)

ASH 2020: Dr. Adrian Wiestner on Early Detection of BTK Mutations Preceding Ibrutinib Relapse in Chronic Lymphocytic Leukemia (CLL)

ASH 2020: Dr. Anthony Mato Discusses the Impact of del(17p) on Survival of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with First-Line Ibrutinib

Driving CARs to the Clinic for Standard Medical Management of Chronic Lymphocytic Leukemia (CLL)

iwCLL 2019: Dr. Nicole Lamanna on Biomarker Testing for Chronic Lymphocytic Leukemia (CLL)

iwCLL 2019: Dr. Constantine Tam on Clonal Evolution in Chronic Lymphocytic Leukemia (CLL)

Cellular Immunotherapy in the Management of Cancer

Didn't find what you where looking for?

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT